Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annu... (R) group and greater than placebo were d...)

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting

Date:12/8/2008

R) group and greater than placebo were dizziness (31 percent vs. 8 percent), headache (13 percent vs. 9 percent), nausea (11 percent vs. 4 percent), and diplopia (11 percent vs. 2 percent).

    -- TEAEs were mild to moderate and appeared to be dose-related.

    -- The incidence of weight gain and other troublesome TEAEs such as
       somnolence and cognitive and psychiatric AEs appeared low:

        -- The incidence of somnolence was 7 percent for the Vimpat(R)-treated
           group vs. 5 percent for placebo

        -- The incidence of memory impairment was 2 percent for both Vimpat(R)
           and placebo groups

        -- The incidence of depression was 2 percent for the Vimpat(R)-treated
           group and 1 percent for placebo

        -- The incidence of weight gain was 1 percent for both Vimpat(R) and
           placebo groups

Poster Session 3, December 8, 2008, 11:30 am - 12:30 pm (Poster 3.245)

V. Biton, N. Fountain, F. Rosenow, A. Gil-Nagel, T. Sullivan, D. Hebert, P. Doty

Clinical Trials, Inc., Little Rock, Arkansas; University of Virginia, Charlottesville, Virginia; Philipps-University, Department of Neurology, Marburg, Germany; Hospital Ruber Internacional, Madrid, Spain; SCHWARZ BIOSCIENCES (a member of the UCB Group), Raleigh, North Carolina

Important safety information about Vimpat(R) in the U.S.

Vimpat(R) tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat(R) injection is indicated as short-term replacement when oral administration is not feasible in these patients. Patients should be advised that Vimpat(R) may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In p
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers

Post Your Comments:

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annu...(R) group and greater than placebo were d...)